Evidence map›Paper›PMID 41589057›Full record

Trial reportDiabetes, obesity & metabolism2026

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.

Massimo Nardone, Erik Moedt, Hiddo J L Heerspink, Michael J Davies, Manon Girard, David Z I Cherney, Marcel H A Muskiet

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Massimo NardoneDepartment of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Erik MoedtDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-3126-3730
Michael J DaviesLexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
Manon GirardLexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
David Z I CherneyDepartment of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-4164-0429
Marcel H A MuskietDepartment of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-4116-555X

Funding

Lexicon Pharmaceuticals, Inc
6 · The paper itself

Abstract

aimsSotagliflozin, an inhibitor of sodium-glucose co-transporter (SGLT)-1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D). MATERIALS AND

methodsThis is a post-hoc analysis of the randomised, double-blinded, placebo-controlled inTandem3 trial, which assessed efficacy of sotagliflozin 400 mg/d versus placebo as an adjunct to insulin. The present biomarker analysis included 362 participants (26%) who had biological samples collected at baseline and week 24. Plasma renin, copeptin, serum N-terminal pro b-type natriuretic peptide (NT-proBNP), and markers of tubular injury, inflammation, haematopoiesis, and iron homeostasis were measured at baseline and following week 24 treatment; fractional excretion of lithium (FE

resultsParticipants were 46 years of age (60% female) with a mean eGFR and median UACR of 88.4 mL/min/1.73 m

conclusionsIn this T1D population, sotagliflozin increased copeptin levels, FE

Indexed as

Diabetes Mellitus, Type 1GlycosidesHypoglycemic AgentsSodiumSodium-Glucose Transporter 2 InhibitorsAdultBiomarkersDiabetic NephropathiesDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateGlycopeptidesHumansInsulinMaleBiomarkerscopeptinsGlycopeptidesGlycosidesHypoglycemic AgentsInsulinNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)PyransReninSodiumSodium-Glucose Transporter 2 Inhibitorssotagliflozinbiomarkersinflammationneurohormonessotagliflozintubular injurytype 1 diabetes

Identifiers

PMID41589057
PMCPMC12992165

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.